The multicenter ERSPC, which began in the mid-1990s, is the largest and most rigorous investigation into the consequences of widespread PSA screening across Europe. The study assembled more than 160,000 men from eight countries, with nearly half recruited from Finland. These long-term data indicate a statistically significant 13% relative reduction in deaths from prostate cancer attributable to PSA screening. This translates to a number needed to screen (NNS) of 456 to prevent a single prostate cancer death—meaning inviting 456 men to PSA testing saves one life from this disease by reducing fatal outcomes.

Professor Anssi Auvinen, a leading epidemiologist at Tampere University, who played a pivotal role in coordinating the Finnish arm of the trial, explains the nuanced findings. “Although the beneficial mortality impact of PSA screening is undeniable, it diminishes over time once organized screening is halted, basically disappearing within nine years,” he notes. This observation challenges assumptions that single or short-term screening rounds provide lasting protection, emphasizing the need for sustained, repeat interventions or alternative risk-stratified approaches.

While the study’s overarching message affirms the life-saving potential of PSA screening, it also vividly illustrates the intrinsic limitations and ethical dilemmas that practitioners face. Chief among these is overdiagnosis, wherein clinically insignificant prostate cancers—tumors so slow-growing they would cause no symptoms or harm during a patient’s expected lifetime—are detected and treated unnecessarily. The consequences of overdiagnosis are far from trivial; they burden patients with treatments that confer no survival advantage but can generate adverse effects such as urinary incontinence, erectile dysfunction, and a reduced quality of life.

To contextualize the screening outcomes further, the ERSPC findings indicate that at the initial screening, 16% of men exhibited elevated PSA levels; however, only 24% of those men were confirmed to have prostate cancer following biopsy. This striking disparity suggests a considerable proportion of diagnostic interventions might be unnecessary, inflicting physical and emotional harms without clear benefits. Such data sharpen the focus on optimizing the screening paradigm to enhance specificity and improve patient selection criteria.

Crucially, the PSA value itself remains a powerful predictive biomarker, not only for the presence of prostate cancer but also for forecasting the risk of prostate cancer mortality. Leveraging this predictive utility, researchers are now advocating for ‘risk-based screening’ models. These involve tailored screening intervals and thresholds based on individual risk profiles rather than applying uniform screening criteria to all men. This nuanced approach aims to maximize detection of aggressive, clinically significant cancers, while minimizing overdiagnosis of indolent cases.

Significant advancements since the ERSPC’s inception—including the integration of multiparametric magnetic resonance imaging (MRI)—have already demonstrated potential to refine screening accuracy further. MRI enables better visualization of prostate anatomy, guiding biopsy decisions and reducing unnecessary procedures. Coupled with risk calculators that integrate PSA levels along with other patient-specific factors such as age, family history, and genetic markers, risk-based screening promises a new era where the trade-offs between harm and benefit are better balanced.

The ERSPC notably included scientific and clinical contributions from renowned institutions across Europe. Finnish collaborators, including Tampere University and University of Helsinki alongside their associated hospitals and the Finnish Cancer Registry, provided key data for this extensive trial. Coordinated by the Erasmus University Medical Centre in Rotterdam, the ERSPC represents a monumental collaborative effort in cancer epidemiology and public health intervention research.

Despite prostate cancer’s status as the most common malignancy among men worldwide and its significant mortality impact—ranking second in Finland and third across Europe—no national PSA screening program currently exists in Finland. The study’s findings have rekindled healthcare policy discussions regarding whether implementing such programs could be justified. The complex balance between reduction in cancer deaths and risk of overdiagnosis and overtreatment is central to these debates.

Many experts emphasize the need for continued research into personalizing screen-and-treat strategies based on evolving biological understanding of prostate cancer. With further innovation in biomarkers, imaging, and genomics, the goal is to create screening paradigms that deliver mortality benefit while preserving patients’ quality of life.

Published in the prestigious New England Journal of Medicine on October 29, 2025, this study sets a new benchmark in our understanding of prostate cancer screening dynamics over more than two decades. The long-term follow-up delivers critical evidence to guide clinicians, policymakers, and patients seeking clarity amid ongoing controversies about whom to screen, when, and how often.

In summary, the ERSPC study reinforces that PSA screening maintains an important role in preventing deaths from prostate cancer but also highlights the significant challenge of overdiagnosis inherent to current methodologies. Future screening programs will likely evolve toward risk-adapted protocols that integrate diagnostic imaging and molecular profiling to maximize benefits while minimizing harms. As prostate cancer remains a leading cause of male cancer mortality, these findings will resonate deeply across medical communities and shape cancer control strategies well into the future.

Subject of Research: Long-term impact of prostate-specific antigen (PSA) screening on prostate cancer mortality and overdiagnosis

Article Title: European Study of Prostate Cancer Screening — 23-Year Follow-up

News Publication Date: 29 October 2025

Web References:

• https://www.nejm.org/doi/full/10.1056/NEJMoa2503223
• http://www.erspc.org/
• https://www.tuni.fi/en/research/finnish-randomized-study-screening-prostate-cancer-finrspc

References:
New England Journal of Medicine, DOI: 10.1056/NEJMoa2503223

Image Credits: Not provided

Keywords: Prostate cancer, PSA screening, overdiagnosis, mortality reduction, risk-based screening, magnetic resonance imaging, ERSPC, prostate-specific antigen, long-term follow-up, cancer epidemiology

Prostate cancer stands as the most frequently diagnosed cancer among men across 112 nations, with projections indicating the prevalence may double by the year 2040. The introduction of national prostate cancer screening initiatives, particularly those predicated on measuring levels of prostate-specific antigen (PSA) in the bloodstream, offers the tantalizing promise of facilitating earlier therapeutic interventions. Early detection can vastly enhance the likelihood of successful treatment and effectively circumscribe the extensive costs associated with managing advanced prostate cancer cases.

Through long-term follow-up data from ERSPC, it has been consistently affirmed that participation in PSA screening programs could correlate with a 20% reduction in the risk of dying from prostate cancer. This is an encouraging statistic that underscores the urgent need for increased participation rates, particularly among demographics traditionally less engaged with health services. The recent sub-analysis of 20 years of data during the ERSPC is pioneering in its examination of the relationship between the consistent rejection of screening invitations and an individual’s risk of mortality due to prostate cancer.

Explorations led by researchers from the Department of Urology at the Erasmus MC Cancer Institute in Rotterdam have revealed that out of a staggering 72,460 men who were invited for screening, approximately one in six—over 12,400 men—chose to skip all scheduled appointments. Alarmingly, this cohort faced a 45% elevated risk of succumbing to prostate cancer compared to their counterparts who participated in the screening process. This stark finding illuminates the potential consequences inherent in the decision to forgo screening, invoking concern about the long-term implications for public health initiatives aimed at combating prostate cancer.

When the outcomes of this group were juxtaposed with a control group—men who were never invited for screening—it was discovered that men who adhered to screening appointments enjoyed a 23% lower risk of death from prostate cancer. Conversely, the non-attendees encountered a 39% greater risk of mortality from this disease. These results emphasize the critical nature of attendance and engagement in screening programs as a determinant of health outcomes among men.

The reluctance to participate in screening appointments may stem from a convoluted array of motivators, ranging from personal beliefs to socio-cultural influences, according to Dr. Renée Leenen, the study’s lead author and a PhD researcher associated with Professor Monique Roobol’s group at the Erasmus MC Cancer Institute. Dr. Leenen articulates a pressing concern that many of those who decline screening are likely care avoiders, reflecting a broader trend of disengagement with not only personal health but also preventive healthcare practices overall.

This research propels forward the understanding that men invited to participate in screening who nevertheless choose to abstain are markedly at an enhanced risk of falling victim to prostate cancer. This information necessitates a pivot in focus in public health strategies aimed at prostate cancer prevention. An imperative persists to delve deeper into the profiles of these men, unraveling the underlying motivations for their lack of participation, and subsequently devising strategies to motivate and empower them towards screening.

Given the findings from the EAU-led PRAISE-U project, multiple EU nations are collectively striving to refine their approaches towards patient-centered, risk-based prostate cancer screening programs. Insights gleaned from this latest analysis underline the paramount importance of improving attendance rates, which are essential for ensuring the efficacy of national prostate cancer screening programs. Notably, addressing disparities in access and awareness is crucial for tapping into the potential of these high-risk groups of men.

Dr. Tobias Nordström, a Clinical Urologist at the Karolinska Institute in Sweden and a member of the EAU Scientific Congress Office, articulates that this new analysis reaffirms the overall advantages of prostate cancer screening are even more pronounced than previously understood. As national prostate screening programs are formulated, the stark implications of non-attendance among certain demographic groups necessitate targeted public health responses. This can be pivotal in altering the trajectory for men identified as being at risk of developing advanced prostate cancer, altering the landscape of treatment and outcomes significantly.

The sub-analysis incorporates a sweeping 20-year follow-up of data collected from 161,000 men aged between 55-69 years within the ERSPC across diverse European nations including Finland, the Netherlands, Italy, Sweden, Switzerland, Belgium, and Spain. The ERSPC, which launched in 1990, has systematically contributed to an evolving understanding of prostate cancer, with full results of this sub-analysis anticipated to be published later this year. As health professionals and researchers work collaboratively to unpack these findings, the implications for screening practices and the potential to enhance outcomes for men at risk remain paramount.

Overall, this research signifies a vital step in illuminating the nuanced relationship between screening participation and prostate cancer mortality risk. As awareness increases, so too does the potential for developing targeted interventions that maximize participation rates. By engaging high-risk groups and effectively addressing barriers to screening attendance, we can foster a more proactive healthcare environment that champions early detection and treatment, thereby reducing the unnecessary mortality burden of prostate cancer in men.

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:

Keywords: Prostate cancer, Cancer screening, Cancer risk, Cancer research, Europe, Urology, Clinical trials